12,552 findings · published 2017+
- Energy balanceStrong
There is no consensus definition for 'failure' in resistance training literature.
Practitioners should be aware of the lack of standardization in training definitions when interpreting research.
Qualifies 2022 - CellularStrong
There was no significant change in telomere length at 6 months.
Weight loss interventions may not affect telomere length in the short term.
Refutes 2020 - MolecularStrong
Reduced microbial diversity in the gut is implicated in several gastrointestinal diseases and cancers.
Maintaining gut microbiome diversity may be crucial for preventing gastrointestinal diseases.
Supports 2025New - Energy balanceStrong
Preoperative use of GLP-1 receptor agonists is not significantly associated with the odds of postoperative aspiration pneumonia.
Clinicians may reconsider the necessity of withholding GLP-1 RAs preoperatively based on these findings.
Refutes 2025New - Energy balanceStrong
Patients using GLP-1 receptor agonists are more likely to be female and diagnosed with both obesity and diabetes compared to nonusers.
Understanding the demographics of GLP-1 RA users can inform targeted interventions and education.
Supports 2025New - Metabolic adaptationStrong
Endoscopic hydrothermal duodenal mucosal resurfacing is well tolerated in human subjects.
Practitioners can consider this procedure as a safe option for patients.
Supports 2017 - Metabolic adaptationStrong
Endoscopic hydrothermal duodenal mucosal resurfacing has an acceptable safety profile.
This procedure can be considered for patients with a focus on safety.
Supports 2017 - HormonalStrong
Use of GLP-1 receptor agonists (GLP-1 RAs) is associated with an increased incidence of diabetic retinopathy (DR) with a hazard ratio (HR) of 1.07 (95% CI, 1.03-1.11).
Clinicians should be aware of the increased risk of DR when prescribing GLP-1 RAs to patients with T2D.
Supports 2025New - HormonalStrong
GLP-1 RAs are not associated with progression to proliferative diabetic retinopathy (HR, 1.06; 95% CI, 0.97-1.15) or diabetic macular edema (HR, 0.98; 95% CI, 0.95-1.01) in patients with preexisting DR.
Patients with preexisting DR may not experience worsening of certain complications when treated with GLP-1 RAs.
Refutes 2025New - CellularStrong
There is a need for more research on the anabolic potential of non-animal-derived protein sources.
More research is needed to evaluate the effectiveness of non-animal protein sources for muscle health.
Supports 2022 - Energy balanceStrong
Trials with both smartphone and in-person components exhibited the highest racial minority enrollment.
Combining technology with in-person interactions may further improve minority enrollment in weight loss trials.
Supports 2017 - Energy balanceStrong
Many racial and ethnic minority groups are under-represented in clinical trials of behavioral weight loss treatment.
Recognizing the under-representation of minorities can guide efforts to improve enrollment in clinical trials.
Supports 2017 - Metabolic adaptationStrong
Biliopancreatic diversion (BPD) and mini gastric bypass (mini-GBP) have the highest diabetes remission rates among the surgical treatments analyzed.
Clinicians should consider BPD and mini-GBP as effective options for achieving diabetes remission in patients.
Supports 2018 - Energy balanceStrong
The results of the analysis should be interpreted with caution due to the minority representation of BPD and mini-GBP among bariatric surgeries.
Practitioners should be aware of the limitations in the data when recommending surgical options.
Qualifies 2018 - Energy balanceStrong
Further research with larger sample sizes is needed to confirm these results.
Practitioners should be aware that current findings are preliminary and require further validation.
Supports 2019 - CellularStrong
INV-202 was well tolerated with no serious or severe treatment-emergent adverse events.
INV-202 appears to be a safe option for individuals with metabolic syndrome.
Supports 2023 - Energy balanceStrong
The number of people living with obesity has tripled worldwide since 1975.
Public health initiatives should address the rising obesity rates.
Supports 2021 - Energy balanceStrong
No dietary intervention was introduced during the experimental period.
The findings are solely attributed to the exercise intervention, emphasizing its effectiveness without dietary influence.
Supports 2018 - Energy balanceStrong
Higher sustained pharmacy costs were the main driver of the cost difference favoring MBS over GLP-1 receptor agonists.
Healthcare providers should consider ongoing medication costs when recommending obesity treatments.
Supports 2025New - Energy balanceStrong
Restrictive diets such as very-low-carb, ketogenic, very-low-calorie diets, and intermittent fasting have scarce evidence for direct benefit to NAFLD.
Practitioners should be cautious in recommending restrictive diets for NAFLD due to insufficient evidence of their benefits.
Refutes 2022 - Energy balanceStrong
The random forest classification algorithm exhibits superior accuracy rates of 97% for Obesity_Type_I, 99% for Obesity_Type_II, and 83% for Obesity_Type_III compared to alternative classifiers.
Practitioners can utilize machine learning algorithms, particularly random forests, for more accurate obesity classification.
Supports 2023 - Energy balanceStrong
The study demonstrates the efficacy of machine learning methodologies in forecasting different forms of obesity.
Machine learning can be a powerful tool for predicting obesity, aiding in prevention and management strategies.
Supports 2023 - MolecularStrong
Tirzepatide does not seem to have a classical co-activating mode of action in humans.
Understanding the unique action of tirzepatide may inform treatment strategies for type 2 diabetes.
Refutes 2023 - Metabolic adaptationStrong
Sleeve gastrectomy has emerged as the most popular bariatric procedure in the last 10 years.
Surgeons should be aware that sleeve gastrectomy is currently the preferred option among patients.
Supports 2023